Genesis Fertility Center Public Company Limited
2.04
THB
+0.04
(+2.00%)
ISIN
THB552010001
Return %
Stock
S&P 500
1Y
-35.03
14.20
3Y
-80.57
81.12
5Y
- -
68.34
Capital Structure
THB
•
in mil. unless spec.Working Capital
THB
•
in mil. unless spec.Growth Rates
THB
•
in mil. unless spec.Quarterly Revenue
THB
•
in mil. unless spec.Quarterly Earnings Per Share
THB
•
in mil. unless spec.Quarterly Dividends Per Share
THB
•
in mil. unless spec.Company Description
- CEO
- Nathee Tungchitsodsai
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- Bangkok Thailand
- IPO Date
- Sep 13, 2023
- Website
- genesisfertilitycenter.co.th
- Similar Companies
- Business
- Genesis Fertility Center Public Company Limited is a Thailand-based healthcare provider specializing in comprehensive assisted reproductive technology (ART) and infertility treatment services. The company provides a full continuum of reproductive medical care and fertility solutions for domestic and international patients, including consultation and fertility diagnostic examinations; intrauterine insemination (IUI); in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI); preimplantation genetic testing (PGT-A and PGT-M) utilizing next-generation sequencing; time-lapse embryo incubation and monitoring; cryopreservation of oocytes, sperm, and embryos; semen analysis and sperm preparation; diagnostic hysteroscopy; and personalized reproductive wellness and nutritional counseling. Founded in 2015 and headquartered in Bangkok, Thailand, Genesis Fertility Center operates specialized fertility clinics equipped with cleanroom laboratories and certified medical embryology facilities. In recent developments, the company completed its initial public offering on the Market for Alternative Investment (mai) of the Stock Exchange of Thailand, raising capital to accelerate physical and technological expansion. Genesis Fertility Center has broadened its clinical network through the establishment of new facilities, including the Rama 9-Srinakarin flagship center in Bangkok and a regional branch in Ubon Ratchathani designed to serve northeastern Thailand and cross-border patients from neighboring countries such as Laos and Cambodia. Furthermore, the company has incorporated artificial intelligence-assisted embryo evaluation tools into its laboratory operations and expanded international patient support services to capture regional demand in medical tourism.